CN104684914B - 吡咯并苯并二氮杂卓 - Google Patents

吡咯并苯并二氮杂卓 Download PDF

Info

Publication number
CN104684914B
CN104684914B CN201380035167.5A CN201380035167A CN104684914B CN 104684914 B CN104684914 B CN 104684914B CN 201380035167 A CN201380035167 A CN 201380035167A CN 104684914 B CN104684914 B CN 104684914B
Authority
CN
China
Prior art keywords
alkyl
methyl
acid
aryl
examples
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CN201380035167.5A
Other languages
English (en)
Chinese (zh)
Other versions
CN104684914A (zh
Inventor
菲利普·威尔逊·霍华德
戴维·瑟斯顿
洪达克·米拉祖尔·拉赫曼
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
MedImmune Ltd
Original Assignee
ADC Therapeutics SA
UCL Biomedica PLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ADC Therapeutics SA, UCL Biomedica PLC filed Critical ADC Therapeutics SA
Publication of CN104684914A publication Critical patent/CN104684914A/zh
Application granted granted Critical
Publication of CN104684914B publication Critical patent/CN104684914B/zh
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
    • A61K31/5517—1,4-Benzodiazepines, e.g. diazepam or clozapine condensed with five-membered rings having nitrogen as a ring hetero atom, e.g. imidazobenzodiazepines, triazolam
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
CN201380035167.5A 2012-04-30 2013-04-30 吡咯并苯并二氮杂卓 Expired - Fee Related CN104684914B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261640310P 2012-04-30 2012-04-30
US61/640,310 2012-04-30
PCT/GB2013/051098 WO2013164593A1 (en) 2012-04-30 2013-04-30 Pyrrolobenzodiazepines

Publications (2)

Publication Number Publication Date
CN104684914A CN104684914A (zh) 2015-06-03
CN104684914B true CN104684914B (zh) 2017-12-15

Family

ID=48325770

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201380035167.5A Expired - Fee Related CN104684914B (zh) 2012-04-30 2013-04-30 吡咯并苯并二氮杂卓

Country Status (14)

Country Link
US (1) US9376440B2 (enExample)
EP (1) EP2855482B1 (enExample)
JP (1) JP6157596B2 (enExample)
KR (1) KR101960129B1 (enExample)
CN (1) CN104684914B (enExample)
AU (1) AU2013255613B2 (enExample)
BR (1) BR112014027143B1 (enExample)
CA (1) CA2871172C (enExample)
ES (1) ES2623042T3 (enExample)
IN (1) IN2014MN02092A (enExample)
MX (1) MX369715B (enExample)
NZ (1) NZ701290A (enExample)
WO (1) WO2013164593A1 (enExample)
ZA (1) ZA201407759B (enExample)

Families Citing this family (55)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0819095D0 (en) 2008-10-17 2008-11-26 Spirogen Ltd Pyrrolobenzodiazepines
CN102971329B (zh) 2010-04-15 2016-06-29 麦迪穆有限责任公司 用于治疗增殖性疾病的吡咯并苯并二氮杂卓
NZ602932A (en) 2010-04-15 2014-08-29 Seattle Genetics Inc Targeted pyrrolobenzodiazapine conjugates
CN103987718A (zh) 2011-09-20 2014-08-13 斯皮罗根有限公司 作为非对称二聚体pbd化合物用于内含在靶向结合物中的吡咯并苯并二氮杂卓
CA2850103C (en) 2011-10-14 2019-09-10 Spirogen Sarl Pyrrolobenzodiazepines
US9388187B2 (en) 2011-10-14 2016-07-12 Medimmune Limited Pyrrolobenzodiazepines
JP6393617B2 (ja) 2011-10-14 2018-09-19 シアトル ジェネティクス，インコーポレーテッド ピロロベンゾジアゼピンおよび標的コンジュゲート
CA2850375C (en) 2011-10-14 2019-07-02 Seattle Genetics, Inc. Pyrrolobenzodiazepines and targeted conjugates
HUE045435T2 (hu) 2012-10-12 2019-12-30 Medimmune Ltd Pirrolobenzodiazepinek és konjugátumaik
CA2885305C (en) 2012-10-12 2019-11-12 Spirogen Sarl Synthesis and intermediates of pyrrolobenzodiazepine derivatives for conjugation
HRP20182129T1 (hr) 2012-10-12 2019-02-08 Adc Therapeutics Sa Konjugati protutijelo - pirolobenzodiazepin
WO2014057073A1 (en) 2012-10-12 2014-04-17 Spirogen Sàrl Pyrrolobenzodiazepines and conjugates thereof
AU2013366493B2 (en) 2012-12-21 2017-08-24 Medimmune Limited Pyrrolobenzodiazepines and conjugates thereof
US9567340B2 (en) 2012-12-21 2017-02-14 Medimmune Limited Unsymmetrical pyrrolobenzodiazepines-dimers for use in the treatment of proliferative and autoimmune diseases
CA2904044C (en) 2013-03-13 2020-03-31 Medimmune Limited Pyrrolobenzodiazepines and conjugates thereof
CN105307685B (zh) 2013-03-13 2019-03-08 麦迪穆有限责任公司 吡咯并苯并二氮杂卓和其结合物
EP2830126B1 (en) * 2013-05-07 2019-07-03 LG Chem, Ltd. Electrode for secondary battery, preparation thereof, and secondary battery and cable-type secondary battery comprising the same
GB201317982D0 (en) 2013-10-11 2013-11-27 Spirogen Sarl Pyrrolobenzodiazepines and conjugates thereof
GB201317981D0 (en) 2013-10-11 2013-11-27 Spirogen Sarl Pyrrolobenzodiazepines and conjugates thereof
GB201407816D0 (en) 2014-05-02 2014-06-18 King S College London Pyrrolobenzodiazepine Compounds
GB201416112D0 (en) 2014-09-12 2014-10-29 Medimmune Ltd Pyrrolobenzodiazepines and conjugates thereof
EP3223854A1 (en) 2014-11-25 2017-10-04 ADC Therapeutics SA Pyrrolobenzodiazepine-antibody conjugates
GB201506411D0 (en) 2015-04-15 2015-05-27 Bergenbio As Humanized anti-axl antibodies
GB201506402D0 (en) 2015-04-15 2015-05-27 Berkel Patricius H C Van And Howard Philip W Site-specific antibody-drug conjugates
GB201510010D0 (en) 2015-06-09 2015-07-22 King S College London PDD and BPD compounds
GB201514928D0 (en) 2015-08-21 2015-10-07 King S College London PDD compounds
US20180339985A1 (en) 2015-08-21 2018-11-29 Femtogenix Limited Pdd compounds
GB201521709D0 (en) * 2015-12-09 2016-01-20 Kings College London And Sec Dep For Health The PBD Antibacterial agents
GB201601431D0 (en) 2016-01-26 2016-03-09 Medimmune Ltd Pyrrolobenzodiazepines
GB201602356D0 (en) 2016-02-10 2016-03-23 Medimmune Ltd Pyrrolobenzodiazepine Conjugates
GB201602359D0 (en) 2016-02-10 2016-03-23 Medimmune Ltd Pyrrolobenzodiazepine Conjugates
GB201607478D0 (en) 2016-04-29 2016-06-15 Medimmune Ltd Pyrrolobenzodiazepine Conjugates
TW201808936A (zh) 2016-05-18 2018-03-16 美商梅爾莎納醫療公司 吡咯并苯并二氮呯類及其共軛物
US10526294B2 (en) 2016-06-24 2020-01-07 Mersana Therapeutics, Inc. Pyrrolobenzodiazepines and conjugates thereof
GB201617466D0 (en) 2016-10-14 2016-11-30 Medimmune Ltd Pyrrolobenzodiazepine conjugates
KR20200032243A (ko) 2017-02-08 2020-03-25 에이디씨 테라퓨틱스 에스에이 피롤로벤조디아제핀-항체 컨주게이트
GB201702031D0 (en) 2017-02-08 2017-03-22 Medlmmune Ltd Pyrrolobenzodiazepine-antibody conjugates
EP3604311A4 (en) 2017-03-29 2021-01-13 LegoChem Biosciences, Inc. PYRROLOBENZODIAZEPINE DIMERIC PRECURSOR AND ASSOCIATED LIGAND-BOND CONJUGATE COMPOUND
SI3612537T1 (sl) 2017-04-18 2022-10-28 Medimmune Limited Konjugati pirolobenzodiazepina
EP3612234B1 (en) 2017-04-20 2024-03-13 ADC Therapeutics SA Combination therapy with an anti-axl antibody-drug conjugate
KR102442736B1 (ko) 2017-06-14 2022-09-16 에이디씨 테라퓨틱스 에스에이 항-cd19 adc의 투여를 위한 투약량 체제
CN111065638B (zh) 2017-08-18 2021-04-09 麦迪穆有限责任公司 吡咯并苯并二氮杂䓬缀合物
IL301638B2 (en) 2017-09-29 2024-09-01 Daiichi Sankyo Co Ltd Antibody-pyrrolobenzodiazepine derivative conjugate
EP3717021A1 (en) 2017-11-27 2020-10-07 Mersana Therapeutics, Inc. Pyrrolobenzodiazepine antibody conjugates
EP3727463A1 (en) 2017-12-21 2020-10-28 Mersana Therapeutics, Inc. Pyrrolobenzodiazepine antibody conjugates
GB201803342D0 (en) 2018-03-01 2018-04-18 Medimmune Ltd Methods
SG11202009308WA (en) 2018-03-28 2020-10-29 Mitsubishi Tanabe Pharma Corp DRUG CONJUGATES OF cMET MONOCLONAL BINDING AGENTS, AND USES THEREOF
GB201806022D0 (en) 2018-04-12 2018-05-30 Medimmune Ltd Pyrrolobenzodiazepines and conjugates thereof
KR20200084802A (ko) 2019-01-03 2020-07-13 주식회사 레고켐 바이오사이언스 안전성이 향상된 피롤로벤조디아제핀 이량체 화합물 및 이의 용도
WO2020141923A2 (ko) 2019-01-03 2020-07-09 주식회사 레고켐 바이오사이언스 안전성이 향상된 피롤로벤조디아제핀 이량체 화합물 및 이의 용도
GB201901197D0 (en) 2019-01-29 2019-03-20 Femtogenix Ltd G-A Crosslinking cytotoxic agents
IL286326B2 (en) 2019-03-15 2025-10-01 Medimmune Ltd Azatidobenzodiazepine dimers and conjugates containing them for use in the treatment of cancer
GB2597532A (en) * 2020-07-28 2022-02-02 Femtogenix Ltd Cytotoxic compounds
AU2023298568A1 (en) 2022-06-30 2025-01-09 Toray Industries, Inc. Pharmaceutical composition for cancer treatment and/or prevention
GB202405758D0 (en) 2024-04-24 2024-06-05 King S College London Compounds

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1735616A (zh) * 2002-11-14 2006-02-15 斯皮罗根有限公司 吡咯并苯并二氮杂䓬
WO2007039752A1 (en) * 2005-10-05 2007-04-12 Spirogen Limited Alkyl 4- [4- (5-oxo-2, 3, 5, 11a-tetrahyd0-5h-pyrr0l0 [2, 1-c] [1, 4] benzodiazepine-8-yloxy) -butyrylamino]-1h-pyrrole-2-carboxylate derivatives and related compounds for the treatment of a proliferative disease
WO2009060208A1 (en) * 2007-11-09 2009-05-14 Spirogen Limited Pyrrolobenzodiazepines

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5569587A (en) 1978-11-17 1980-05-26 Meiji Seika Kaisha Ltd Novel antibiotic neothramycin derivative and its preparation
JPS58180487A (ja) 1982-04-16 1983-10-21 Kyowa Hakko Kogyo Co Ltd 抗生物質ｄｃ−８１およびその製造法
US5229490A (en) 1987-05-06 1993-07-20 The Rockefeller University Multiple antigen peptide system
DE69720773T2 (de) 1996-12-23 2004-01-29 Bristol Myers Squibb Pharma Co SAUERSTOFF ODER SCHWEFEL ENTHALTENDE 5-GLIEDRIGE HETEROAROMATISHE DERIVATIVE ALS FACTOR Xa HEMMER
US6187797B1 (en) 1996-12-23 2001-02-13 Dupont Pharmaceuticals Company Phenyl-isoxazoles as factor XA Inhibitors
WO1999046244A1 (en) 1998-03-12 1999-09-16 Novo Nordisk A/S Modulators of protein tyrosine phosphatases (ptpases)
GB9818730D0 (en) 1998-08-27 1998-10-21 Univ Portsmouth Collections of compounds
GB9818731D0 (en) 1998-08-27 1998-10-21 Univ Portsmouth Compounds
DK1193270T3 (da) 1998-08-27 2003-09-15 Spirogen Ltd Pyrrolobenzodiazepiner
GB9818732D0 (en) 1998-08-27 1998-10-21 Univ Portsmouth Collection of compounds
US6909006B1 (en) 1999-08-27 2005-06-21 Spirogen Limited Cyclopropylindole derivatives
MXPA02005937A (es) 1999-12-20 2004-08-12 Univ North Carolina Compuestos de diamina como aglutinantes de surco menor.
US20040138269A1 (en) 2002-10-11 2004-07-15 Sugen, Inc. Substituted pyrroles as kinase inhibitors
GB0321295D0 (en) 2003-09-11 2003-10-15 Spirogen Ltd Synthesis of protected pyrrolobenzodiazepines
GB0404577D0 (en) 2004-03-01 2004-04-07 Spirogen Ltd Pyrrolobenzodiazepines
GB0404578D0 (en) 2004-03-01 2004-04-07 Spirogen Ltd Pyrrolobenzodiazepines
GB0404574D0 (en) 2004-03-01 2004-04-07 Spirogen Ltd Amino acids
CA2558195C (en) 2004-03-01 2012-11-06 Spirogen Limited 11-hydroxy-5h-pyrrolo[2,1-c][1,4]benzodiazepin-5-one derivatives as key intermediates for the preparation of c2 substituted pyrrolobenzodiazepines
JP5166861B2 (ja) 2004-03-09 2013-03-21 スピロゲン リミティッド ピロロベンゾジアゼピン
GB0410725D0 (en) 2004-05-13 2004-06-16 Spirogen Ltd Pyrrolobenzodiazepine therapeutic agents
AU2006238686B2 (en) 2005-04-21 2011-10-06 Medimmune Limited Pyrrolobenzodiazepines
DE102007029116A1 (de) * 2007-06-25 2009-01-02 Continental Automotive Gmbh Verfahren zum Betreiben eines Mikrocontrollers und einer Ausführungseinheit sowie ein Mikrocontroller und eine Ausführungseinheit
GB0813432D0 (en) 2008-07-22 2008-08-27 Spirogen Ltd Pyrrolobenzodiazepines
GB0819095D0 (en) 2008-10-17 2008-11-26 Spirogen Ltd Pyrrolobenzodiazepines

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1735616A (zh) * 2002-11-14 2006-02-15 斯皮罗根有限公司 吡咯并苯并二氮杂䓬
WO2007039752A1 (en) * 2005-10-05 2007-04-12 Spirogen Limited Alkyl 4- [4- (5-oxo-2, 3, 5, 11a-tetrahyd0-5h-pyrr0l0 [2, 1-c] [1, 4] benzodiazepine-8-yloxy) -butyrylamino]-1h-pyrrole-2-carboxylate derivatives and related compounds for the treatment of a proliferative disease
WO2009060208A1 (en) * 2007-11-09 2009-05-14 Spirogen Limited Pyrrolobenzodiazepines

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
Antistaphylococcal activity of DNA-interactive pyrrolobenzodiazepine (PBD) dimers and PBD-biaryl conjugates;Khondaker M. Rahman，等;《J Antimicrob Chemother》;20120430;第67卷(第7期);第1683-1696页 *
GC-Targeted C8-Linked Pyrrolobenzodiazepine−Biaryl Conjugates with Femtomolar in Vitro Cytotoxicity and in Vivo Antitumor Activity in Mouse Models;Khondaker M. Rahman,等;《Journal of Medicinal Chemistry》;20130321;第56卷(第7期);第2911-2935页 *

Also Published As

Publication number Publication date
EP2855482A1 (en) 2015-04-08
HK1208444A1 (en) 2016-03-04
WO2013164593A1 (en) 2013-11-07
AU2013255613B2 (en) 2017-06-22
JP6157596B2 (ja) 2017-07-05
NZ701290A (en) 2016-08-26
US20150133435A1 (en) 2015-05-14
CA2871172C (en) 2020-08-25
KR101960129B1 (ko) 2019-03-19
MX369715B (es) 2019-11-20
BR112014027143B1 (pt) 2020-06-09
EP2855482B1 (en) 2017-03-01
ES2623042T3 (es) 2017-07-10
JP2015515972A (ja) 2015-06-04
ZA201407759B (en) 2015-11-25
MX2014013098A (es) 2015-04-14
US9376440B2 (en) 2016-06-28
CN104684914A (zh) 2015-06-03
KR20150016245A (ko) 2015-02-11
AU2013255613A1 (en) 2014-11-13
IN2014MN02092A (enExample) 2015-09-04
CA2871172A1 (en) 2013-11-07
BR112014027143A2 (pt) 2017-06-27

Similar Documents

Publication Publication Date Title
CN104684914B (zh) 吡咯并苯并二氮杂卓
ES2338696T3 (es) Pirrolobenzodiazepinas.
ES2557283T3 (es) Dímeros de pirrolbenzodiazepinas asimétricas para el tratamiento de enfermedades proliferativas
CN104540827B (zh) 吡咯并苯并二氮杂卓
ES2623057T3 (es) Pirrolobenzodiazepinas usadas para tratar enfermedades proliferativas
EP1931671B1 (en) Alkyl 4- [4- (5-oxo-2, 3, 5, 11a-tetrahyd0-5h-pyrr0l0 [2, 1-c][1, 4]benzodiazepine-8-yloxy) -butyrylamino]-1h-pyrrole-2-carboxylate derivatives and related compounds for the treatment of a proliferative disease
JP4909258B2 (ja) Ｃ２置換ピロロベンゾジアゼピン類を調製するための主要な中間体としての１１−ヒドロキシ−５Ｈ−ピロロ［２，１−ｃ］［１，４］ベンゾジアゼピン−５−オン誘導体
HK1208444B (en) Pyrrolobenzodiazepines
HK1154575B (en) Unsymmetrical pyrrolobenzodiazepine-dimers for treatment of proliferative diseases

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C41 Transfer of patent application or patent right or utility model
CB02 Change of applicant information

Address after: Lausanne

Applicant after: SPIROGEN Ltd.

Applicant after: UCL BUSINESS PLC

Address before: Switzerland at Kiel Xie Texas

Applicant before: Spirogen Ltd.

Applicant before: UCL BUSINESS PLC

COR Change of bibliographic data
TA01 Transfer of patent application right

Effective date of registration: 20160127

Address after: cambridge

Applicant after: MEDIMMUNE LTD.

Applicant after: UCL BUSINESS PLC

Address before: Lausanne

Applicant before: Spirogen Ltd.

Applicant before: UCL BUSINESS PLC

GR01 Patent grant
GR01 Patent grant
TR01 Transfer of patent right
TR01 Transfer of patent right

Effective date of registration: 20200113

Address after: England

Patentee after: MEDIMMUNE LTD.

Address before: England

Co-patentee before: UCL BUSINESS PLC

Patentee before: MEDIMMUNE LTD.

CF01 Termination of patent right due to non-payment of annual fee
CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20171215

Termination date: 20210430